Digital health's point-solution era is giving way to broader platforms, and the cost-savings claims those platforms make to employers often don't hold up to methodological scrutiny.
News|Articles|June 8, 2026
What Pharma Leaders Must Get Right for Supply Chain Modernization Strategy
Author(s)PwC
Global disruption, drug shortages, geopolitical risk, and cost pressures have pushed pharma supply chains into the spotlight. What was once an operational function is now a direct driver of revenue, launch success, and investor confidence. Pharmaceutical Executive® sat down with Rafael Lander, Principal, Pharmaceutical & Life Sciences Supply Chain and Operations at PwC US, to explore how leading pharma and biotech organizations are modernizing their supply chains to improve resilience, accelerate launches, and protect margins. This is all done without compromising compliance or patient service. From AI-enabled forecasting to digitally connected quality operations, this conversation covers what is delivering results today and where executives should place their focus.
Key Objectives:
- Understand why supply chain modernization is a strategic imperative for life sciences companies
- Learn what differentiates high-performing pharma supply chains from others
- Identify practical actions leaders can take and implement within the next 6-12 months
Related to this article
CORXEL’s Dr. Bo Liang on why efficacy is no longer obesity medicine's biggest gap — and the four unmet needs that define what comes next.
MRD Testing Is Becoming the Most Important Tool in Oncology Drug Development: Q&A with Eric Matthews
MRD testing is transforming oncology trials — compressing timelines, enriching populations, and generating earlier answers.
Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide sellers, and Avi Pardo flags a compliance blind spot in field teams' text messages with doctors.
Dr. Jeremy Levin joins Ken Banta to share why he believes biotech's future demands a new level of leadership and stakeholder education — and why "mission without method" is a wasted effort.
Real-world data from Novo's Octane study show patients who switched from injectable GLP-1 therapy to oral semaglutide lost an average of 4.1% of their body weight within three months.
Numerof's Michael Abrams on why directing employees to the most effective, economical clinicians is digital health's most valuable offering.
Life sciences spends billions on compliance — but WhatsApp, iMessage, and SMS conversations between field teams and HCPs remain invisible to oversight.
Trending on PharmExec
1
Novo Reports Real-World Data Showing Weight Loss After Switch to Oral Semaglutide Pill
2
Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics
3
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
4
As Peptide Rulemaking Stalls, FDA Enforcement Moves Forward
5